Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.74 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.74 |
| ▸ | PSMB5 | P28074 | 16/20 | 0.43 |
| ▸ | PSMB2 | P49721 | 9/20 | 0.43 |
| ▸ | TERF2 | Q15554 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22677333 | 0.98 | KDM1A (0.74) | KDM1ARCOR1PSMB5PSMB2TERF2 | |
| SCHEMBL22677663 | 0.96 | KDM1A (0.72) | KDM1ARCOR1PSMB5PSMB2TERF2 | |
| SCHEMBL24270429 | 0.96 | KDM1A (0.67) | KDM1ARCOR1PSMB5PSMB2 | |
| SCHEMBL22677303 | 0.96 | KDM1A (0.67) | KDM1ARCOR1PSMB5PSMB2 | |
| SCHEMBL22677545 | 0.96 | KDM1A (0.67) | KDM1ARCOR1PSMB5PSMB2 | |
| SCHEMBL22677706 | 0.95 | KDM1A (0.71) | KDM1ARCOR1PSMB5PSMB2TERF2 | |
| SCHEMBL22678333 | 0.95 | KDM1A (0.70) | KDM1ARCOR1PSMB5PSMB2TERF2 | |
| SCHEMBL22677631 | 0.95 | KDM1A (0.70) | KDM1ARCOR1PSMB5PSMB2TERF2 | |
| SCHEMBL22677712 | 0.95 | KDM1A (0.69) | KDM1ARCOR1PSMB5PSMB2TERF2 | |
| SCHEMBL24270415 | 0.94 | KDM1A (0.67) | KDM1ARCOR1PSMB5PSMB2TERF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11279733-B2 | Peptide antibiotics | THE UNIVERSITY OF QUEENSLAND (AU) | 2022-03-22 | — | — | US | disclosed |
| US-20200361994-A1 | PEPTIDE ANTIBIOTICS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361994-A1 | PEPTIDE ANTIBIOTICS | NGLY1, VIP, PEPD | KDM1A 4796/4885RCOR1 4836/4885PSMB5 1250/4885 |
| US-11279733-B2 | Peptide antibiotics | NGLY1, VIP, PEPD | KDM1A 4796/4885RCOR1 4836/4885PSMB5 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.